Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01096901 · ClinicalTrials.gov registry record · Early Phase 1
Choose to Lose for Women-Weight Loss to Reduce Breast Cancer Risk Factors
A Early Phase 1 study, sponsored by California Polytechnic State University-San Luis Obispo.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 19
- Enrollment target
NCT01096901: Completed Early Phase 1 study, sponsored by California Polytechnic State University-San Luis Obispo.
NCT01096901 is a Early Phase 1 study that has completed, run by California Polytechnic State University-San Luis Obispo. The registered enrollment target is 19 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01096901, a Early Phase 1 study, has completed, sponsored by California Polytechnic State University-San Luis Obispo.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is investigating the changes in specific hormone levels in women age 30-45 after a 12 week weight loss intervention.
Primary Outcome
One group in this randomized study will be focused on weight loss during a 3 month period. The goal is to acheive a 6% weight loss during this time. Specific blood draws will be conducted pre and post weight loss to measure any hormonal changes due to this weight loss.
Interventions
- BEHAVIORAL Behavioral Weight loss
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-06 |
| Phase | Early Phase 1 |
What the finished NCT01096901 record still lists
NCT01096901 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 1 intervention - of which Behavioral Weight loss is the first listed.
NCT01096901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01096901 about?
NCT01096901 is a clinical study titled "Choose to Lose for Women-Weight Loss to Reduce Breast Cancer Risk Factors". This study is investigating the changes in specific hormone levels in women age 30-45 after a 12 week weight loss intervention.
What is the current status of trial NCT01096901?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 19 participants. The study started on 2010-11. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01096901?
The interventions under investigation include: Behavioral Weight loss (BEHAVIORAL).
Who is sponsoring clinical trial NCT01096901?
This trial is sponsored by California Polytechnic State University-San Luis Obispo, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01096901's enrollment target sits among peer trials
19 1292nd of 2000 higher than 686 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia